[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse KHDRBS1

Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Membrane Note=Predominantly located in the nucleus but also located partially in the cytoplasm.
Domain PF00013 KH domain
PF16274 Qua1 domain
PF16568 Tyrosine-rich domain of Sam68
Function

Recruited and tyrosine phosphorylated by several receptor systems, for example the T-cell, leptin and insulin receptors. Once phosphorylated, functions as an adapter protein in signal transduction cascades by binding to SH2 and SH3 domain-containing proteins. Role in G2-M progression in the cell cycle. Represses CBP-dependent transcriptional activation apparently by competing with other nuclear factors for binding to CBP. Also acts as a putative regulator of mRNA stability and/or translation rates and mediates mRNA nuclear export. Positively regulates the association of constitutive transport element (CTE)-containing mRNA with large polyribosomes and translation initiation. According to some authors, is not involved in the nucleocytoplasmic export of unspliced (CTE)-containing RNA species according to (PubMed:22253824). RNA-binding protein that plays a role in the regulation of alternative splicing and influences mRNA splice site selection and exon inclusion. Binds to RNA containing 5'-[AU]UAA-3' as a bipartite motif spaced by more than 15 nucleotides. Binds poly(A). Can regulate CD44 alternative splicing in a Ras pathway-dependent manner (By similarity). In cooperation with HNRNPA1 modulates alternative splicing of BCL2L1 by promoting splicing toward isoform Bcl-X(S), and of SMN1 (PubMed:17371836, PubMed:20186123). Can regulate alternative splicing of NRXN1 and NRXN3 in the laminin G-like domain 6 containing the evolutionary conserved neurexin alternative spliced segment 4 (AS4) involved in neurexin selective targeting to postsynaptic partners. In a neuronal activity-dependent manner cooperates synergistically with KHDRBS2/SLIM-1 in regulation of NRXN1 exon skipping at AS4. The cooperation with KHDRBS2/SLIM-1 is antagonistic for regulation of NXRN3 alternative splicing at AS4 (By similarity). ; FUNCTION: Isoform 3, which is expressed in growth-arrested cells only, inhibits S phase.

> Gene Ontology
 
Biological Process GO:0000086 G2/M transition of mitotic cell cycle
GO:0006397 mRNA processing
GO:0006403 RNA localization
GO:0006405 RNA export from nucleus
GO:0006413 translational initiation
GO:0006417 regulation of translation
GO:0006446 regulation of translational initiation
GO:0006913 nucleocytoplasmic transport
GO:0007050 cell cycle arrest
GO:0010608 posttranscriptional regulation of gene expression
GO:0015931 nucleobase-containing compound transport
GO:0032239 regulation of nucleobase-containing compound transport
GO:0032241 positive regulation of nucleobase-containing compound transport
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044839 cell cycle G2/M phase transition
GO:0045727 positive regulation of translation
GO:0045786 negative regulation of cell cycle
GO:0045948 positive regulation of translational initiation
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0046831 regulation of RNA export from nucleus
GO:0046833 positive regulation of RNA export from nucleus
GO:0050657 nucleic acid transport
GO:0050658 RNA transport
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051236 establishment of RNA localization
Molecular Function GO:0003727 single-stranded RNA binding
GO:0005070 SH3/SH2 adaptor activity
GO:0008143 poly(A) binding
GO:0008187 poly-pyrimidine tract binding
GO:0008266 poly(U) RNA binding
GO:0017124 SH3 domain binding
GO:0030674 protein binding, bridging
GO:0035591 signaling adaptor activity
GO:0060090 binding, bridging
GO:0070717 poly-purine tract binding
Cellular Component GO:0070618 Grb2-Sos complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8849468: PTK6 Regulates Proteins Involved in RNA Processing
R-HSA-162582: Signal Transduction
R-HSA-8848021: Signaling by PTK6
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KHDRBS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KHDRBS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.85 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KHDRBS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1520.362
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2130.939
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1110.957
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3910.32
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3050.891
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5050.865
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0230.958
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0470.982
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0120.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3480.85
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6870.806
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1210.00443
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KHDRBS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277302.7-2.71
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275903.4-3.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KHDRBS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KHDRBS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KHDRBS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KHDRBS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KHDRBS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KHDRBS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKHDRBS1
NameKH domain containing, RNA binding, signal transduction associated 1
Aliases Sam68; FLJ34027; GAP-associated tyrosine phosphoprotein p62 (Sam68); p21 Ras GTPase-activating protein-assoc ......
Chromosomal Location1p32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KHDRBS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.